Clinical Gastroenterology Journal

Department of Surgery, Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, United States

Publications

• Research Article   
  A Phase I Study of Immune Checkpoint Inhibition (anti- CTLA4 and anti-PD-L1) in Combination with Radiation Therapy in Patients with Locally Advanced Unresectable Pancreatic Cancer
  Author(s): Jennifer Wu*, Emily C Atkinson, Kevin Du, Susanna Nguy, Anna C Pavlick, Judith D Goldberg, Daniel Becker, Elaine Shum, Steve Y Lee, George Miller, Jennifer Chuy and Lawrence Leichman
  
  Background: No clear consensus exists on the best treatment for unresectable locally advanced pancreatic cancer. Programmed death ligand-1 (PD-L1) inhibitors and cytotoxic T lymphocyte antigen-4 (CTLA-4) inhibitors, especially in combination, have been shown to increase survival in a variety of cancers. Preclinical data indicates potential synergy between immunotherapy, such as PD-L1 and CTLA-4 inhibitors, with radiation therapy. Specifically, in combination with Stereotactic Body Radiation Therapy (SBRT), immunotherapy may provide an effective treatment modality for this difficult-to-treat patient population. Aim: To determine the safety and recommended phase 2 dose (RP2D) of SBRT in combination with either (A) Durvalumab (MEDI4736) alone, (B) Tremelimumab alone or (C) the combination of Durvalumab (MEDI4736) and Tremelimumab for .. Read More»
  DOI: 10.37421/cgj.2020.5.125

  Abstract HTML PDF